Ascendis Pharma A/S (NASDAQ:ASND) Receives Overweight Rating from Cantor Fitzgerald

Cantor Fitzgerald reissued their overweight rating on shares of Ascendis Pharma A/S (NASDAQ:ASND) in a report published on Friday,Benzinga reports. Cantor Fitzgerald currently has a $170.00 target price on the biotechnology company’s stock.

Several other analysts also recently issued reports on ASND. Citigroup raised their price objective on shares of Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a “buy” rating in a research note on Tuesday, September 17th. Evercore ISI raised their price objective on shares of Ascendis Pharma A/S from $191.00 to $205.00 and gave the stock an “outperform” rating in a research note on Tuesday, September 17th. Wedbush reissued an “outperform” rating and issued a $181.00 price objective on shares of Ascendis Pharma A/S in a research note on Friday. Wells Fargo & Company lifted their price target on shares of Ascendis Pharma A/S from $264.00 to $289.00 and gave the company an “overweight” rating in a research note on Tuesday, September 17th. Finally, StockNews.com downgraded shares of Ascendis Pharma A/S from a “hold” rating to a “sell” rating in a research note on Tuesday, November 12th. One analyst has rated the stock with a sell rating, one has issued a hold rating and twelve have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $191.77.

Ascendis Pharma A/S Trading Down 3.6 %

Shares of NASDAQ:ASND opened at $122.00 on Friday. Ascendis Pharma A/S has a 12 month low of $90.13 and a 12 month high of $161.00. The company has a 50-day moving average price of $132.40 and a 200 day moving average price of $132.47. The company has a market cap of $7.40 billion, a price-to-earnings ratio of -15.10 and a beta of 0.66.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings data on Tuesday, September 3rd. The biotechnology company reported ($2.05) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.54) by ($0.51). The business had revenue of $38.75 million for the quarter, compared to analyst estimates of $94.74 million. As a group, equities analysts forecast that Ascendis Pharma A/S will post -7.3 EPS for the current year.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several institutional investors have recently bought and sold shares of ASND. Groupama Asset Managment purchased a new position in Ascendis Pharma A/S during the third quarter valued at approximately $60,000. Signaturefd LLC increased its holdings in Ascendis Pharma A/S by 13.2% during the third quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock valued at $102,000 after buying an additional 80 shares during the period. Bessemer Group Inc. increased its holdings in Ascendis Pharma A/S by 61.0% during the first quarter. Bessemer Group Inc. now owns 876 shares of the biotechnology company’s stock valued at $132,000 after buying an additional 332 shares during the period. Searle & CO. purchased a new position in Ascendis Pharma A/S in the second quarter worth $205,000. Finally, Rhumbline Advisers grew its holdings in Ascendis Pharma A/S by 10.3% in the second quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock worth $209,000 after purchasing an additional 143 shares during the last quarter.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.